Pfizer

#Enodia Therapeutics #Pfizer #Protein degradation #Sec61 inhibitors #Small molecules

Enodia Therapeutics and Pfizer to develop Sec61-targeting small molecules 

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors.   The collaboration aims to accelerate the discovery and advancement of novel small-molecule… Read More

#News

#Collaboration #Innovent #Oncology #Pfizer

Pfizer and Innovent Biologics ink $10.5 billion oncology deal

Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion.  The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads… Read More

#Business & Investment #News #Trending News

#GLP-1 #Mergers and acquisitions #Pfizer #Weight loss

Pfizer boosts weight loss pipeline with GLP-1 drug

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of ShangAhai Fosun Pharmaceutical, for the development, manufacturing and commercialisation of YP05002.  YP05002 is a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management. Read More

#Business & Investment #News

Metsera logo
#Mergers and acquisitions #Metsera #Novo Nordisk #Obesity #Pfizer #Weight loss

Pfizer finally wins bidding war to acquire Metsera

Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera’s Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement… Read More

#Business & Investment #News #Trending News

#AstraZeneca #Biopharma #Direct-to-Consumer #Pfizer #Pharmaceutical industry #United States

Pharma firms offer discounts of up to 85% to US patients

AstraZeneca has become the latest company to lower the cost of medicines for American patients. The company recently announced an agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients “while preserving America’s cutting-edge biopharmaceutical innovation”.  In July, US President Donald… Read More

#Business & Investment #Editor's Choice #News

Pfizer, New York
#Clinical trial #GLP-1 #Pfizer #Weight loss

Pfizer discontinues oral GLP-1 receptor agonist danuglipron

Pfizer has announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, due to drug-induced liver injury.  Danuglipron (PF-06882961) was being investigated for chronic weight management.  The company’s dose-optimisation studies of once-daily formulations of danuglipron met key pharmacokinetic objectives and… Read More

#Business & Investment #News #Trending News

Therapeutic antibodies
#IsomAb #Pfizer #Therapeutic Antibodies

Pfizer supports antibody for peripheral arterial disease

UK-based biotechnology company IsomAb has announced the nomination of a development candidate for peripheral arterial disease (PAD), therapeutic antibody ISM-001. ISM-001 is designed to neutralise VEGF-A165b, the anti-angiogenic VEGF-A splice isoform which acts as a brake on development of new blood vessels leading to chronic limb… Read More

#News

#Contract Research Organisations (CROs) #Discovery Park #Life sciences #Pfizer #Start-ups

Three new life science start-ups join Discovery Park

A group of former Pfizer employees have created their own businesses based at and supported by Discovery Park, a life sciences community in Kent, UK. The new businesses are all contract research organisations (CROs), namely Biowaived, Matheus Engineering and Particology. Their launch has been supported by… Read More

#Business & Investment #News #Start-up Zone

#Cardiovascular disease #Collaboration #Drug discovery #Flagship Pioneering #Partnership #Pfizer

Flagship and Quotient partner on cardiovascular disease therapies

Pfizer has expanded its strategic partnership with Flagship Pioneering, adding two new research programmes with Flagship-founded Quotient Therapeutics. Under the collaboration, the companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. Read More

#Business & Investment #News

#Collaboration #Evotec #France #Infectious diseases #Pfizer

Evotec and Pfizer collaborate on metabolic and infectious diseases

Evotec and Pfizer have entered into a multi-year research collaboration, initially focused on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse with capabilities spanning high throughput screening, in vitro and… Read More

#Business & Investment #News

Weight loss and obesity
#Collaboration #Flagship Pioneering #Obesity #Pfizer #ProFound Therapeutics

Breakthrough drug discovery research collaboration in obesity

Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023. Pioneering Medicines,… Read More

#News

#Arvinas #Breast cancer #FDA #Oncology #Pfizer #PROTAC #Protein degradation

PROTAC degrader for ER+/HER2- breast cancer gets fast-tracked

Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor… Read More

#Cancer Research #News #Regulatory

Bladder cancer
#Antibody drug conjugate (ADC) #Astellas Pharma #Bladder cancer #FDA #Oncology #Pfizer #Phase III trial

Bladder cancer therapy reduces risk of death by 50%

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). The approval is based on clinical data which found that Padcev plus pembrolizumab nearly doubled median… Read More

#Editor's Choice #News #Regulatory

#AI / data analytics / healthtech / informatics #Big pharma #BioNTech #Biopharmaceuticals #Comirnaty #Covid-19 #Drug discovery #Healthcare #Moderna #mRNA #Pfizer

New podcast on drug discovery trends

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More

#News

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Pfizer #United States #Vaccines

US CDC recommends five-in-one meningococcal vaccine

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups. These serogroups cause the majority of… Read More

#News